Characterisation, Measurement and Biodistribution of an Improved Formulation of [Lu-177]-Octreotate
#1156
Introduction: Lu-177 can be made with high specific activity and no other isotopes of lutetium present, referred to as “no carrier added” (nca) Lu-177. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate (Auspep, Melb., AUS) with nca Lu-177 (“nca-LuTATE”) and used it in over 30 administrations in NETs patients.
Aim(s): Initial report on the accuracy, biodistribution and dosimetry of nca-LuTATE from gamma camera 2D whole body (WB) and quantitative 3D SPECT (qSPECT) Lu-177 imaging.
Materials and methods: Ten patients received >30 nca-LuTATE injections made with an E&Z PharmTracer automated module. Extensive WB planar and qSPECT imaging was validated in vivo at 0.5, 4, 24 and 96 hrs to permit estimates of radiation dose using MIRD-based methodology (OLINDA-EXM).
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Bailey D
Authors: Bailey D, Willowson K, Hennessy T, Schembri G, Snowdon G,
Keywords: lutetium, dosimetry, biodistribution, effective dose,
To read the full abstract, please log into your ENETS Member account.